<DOC>
	<DOCNO>NCT00002253</DOCNO>
	<brief_summary>The primary objective study determine relapse rate patient AIDS-related diarrhea find `` Responders '' previous placebo-controlled , double-blind study Sandostatin ( Study # D203 - FDA 102A ) . The secondary objective include : 1 ) To evaluate clinical efficacy safety open-label Sandostatin patient `` Non-Responders '' Study # D203 - FDA 102A ; 2 ) To evaluate efficacy safety Sandostatin prolong open-label treatment `` Responders '' Study # D03 - FDA 102A .</brief_summary>
	<brief_title>A Multicenter Placebo-Controlled Double Blind Study Evaluate Efficacy Safety Sandostatin ( SMS 201-995 ) Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either `` Responders '' `` Non-Responders '' Prior Placebo-Controlled Double-Blind Sandostatin Study .</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Inclusion Criteria Patients must follow : Only patient complete duration Study D203 , FDA 102A eligible study . Each patient must give write informed consent participate Study D204 , FDA 102B well .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1992</verification_date>
	<keyword>Octreotide</keyword>
	<keyword>Diarrhea</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>